Loading
An ADC that delivers a protein-destroying molecule instead of chemotherapy, hitting targets inside the cell that were previously unreachable.
A degrader-antibody conjugate is an ADC whose payload is a molecular glue or PROTAC rather than a cytotoxic: the antibody delivers it to the tumour cell and intracellular release triggers targeted protein degradation. Programmes include Orum Therapeutics (ORM-5029, a HER2-directed GSPT1 degrader; ORM-6151, CD33), Genentech (BRD4 degrader conjugates), and others. The design solves the delivery and bioavailability problems of PROTACs and lets a non-cytotoxic, non-genotoxic mechanism be targeted to the tumour, reaching intracellular targets via antibody selectivity. The trade-off is that potency per molecule is lower than for cytotoxics, and the field is early clinical, so it is not yet known whether degradation can match chemotherapy payloads in efficacy. The simple version is an ADC that destroys a specific protein inside the cancer cell instead of poisoning it.
Antibody delivers a molecular glue or PROTAC payload; intracellular release triggers targeted degradation.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"degrader-antibody conjugate" OR ABSTRACT:"degrader-antibody conjugate" OR TITLE:"degrader antibody conjugate" OR ABSTRACT:"degrader antibody conjugate"). Results are unfiltered search hits about Degrader-antibody conjugate (DAC), not a curated reading list.
Shares Antibody-oligonucleotide conjugates, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall and the tag frontier.
Shares Efflux-agnostic therapy for mesenchymal TNBC, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag frontier.
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag frontier.